{"filings":[{"id":200406,"accession_number":"0001171843-24-006863","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Psychemedics closes stock purchase with 3K LP; repurchases shares for fractional split coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3K Limited Partnership bought 1,409,712 shares at $2.35 on Dec 3, 2024.","Company repurchased 320,708 shares from 3K on Dec 10, 2024 at same $2.35 price.","Funds used to buy fractional shares from reverse stock split and provide $500K working capital.","Transaction closed with Peter Kamin entities, including trusts and a foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200405,"accession_number":"0001171843-24-006701","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Psychemedics executes reverse/forward stock split, plans Nasdaq delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock split effective Dec 3, 2024: 1-for-5,000 reverse split followed by 5,000-for-1 forward split.","Holders of fewer than 5,000 pre-split shares receive $2.35 per share in cash and are cashed out.","Stockholders with 5,000 or more shares see no net change in share count.","Company intends to voluntarily delist from Nasdaq and deregister, filing Form 25 and Form 15.","Expected annual cost savings exceeding $845,000 from delisting and deregistration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200404,"accession_number":"0001171843-24-006571","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Psychemedics shareholders approve reverse-forward stock split and ratify stock purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected five directors: Robyn C. Davis, Brian Hullinger, Peter H. Kamin, Darius G. Nevin, Andrew M. Reynolds with votes ranging 3.70–3.73M for.","Approved reverse stock split (ratio 1:4,000–6,000) and immediate forward split (4,000–6,000:1); Board sets exact ratio.","Ratified Stock Purchase Agreement dated Aug 12, 2024, with 2,981,855 for vs 1,091,026 against.","Non-binding advisory vote on executive compensation passed with 3,654,822 for; auditor Whitley Penn LLP ratified for FY 2024.","Reverse split vote: 3,002,727 for, 1,099,996 against; broker non-votes 1,104,904."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200403,"accession_number":"0001171843-24-006285","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q3 revenue falls 9% to $5.2M; net loss narrows to $0.5M from $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $5.2M, down 9% YoY from $5.7M; nine-month revenue $15.3M, down 11%.","Net loss narrowed to $0.5M ($0.09/share) vs $2.1M ($0.36/share) in prior-year Q3.","Nine-month net loss $2.1M ($0.35/share) vs $3.2M ($0.56/share) in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":15260000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216433,"accession_number":"0001171843-24-004747","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q2 revenue down 15% to $4.7M; net loss widens to $0.14/sh","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $4.7M vs $5.5M YoY (-15%); net loss $0.8M ($0.14/sh) vs $0.7M ($0.13/sh).","H1 2024 revenue $10.1M vs $11.4M YoY (-12%); net loss $1.5M ($0.26/sh) vs $1.1M ($0.19/sh).","CEO cites continued lower client hiring as primary driver of revenue decline.","Company adjusting operating costs while seeking new markets and applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10085000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216432,"accession_number":"0001171843-24-004695","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Psychemedics board approves going-private transaction via reverse stock split, cash-out at $2.35/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio between 1:4,000 and 1:6,000; shares below ratio denominator cashed out at $2.35 each.","Estimated 1.2M shares (21% of outstanding) cashed out, aggregate cost ~$2.8M plus ~$700k expenses.","Company expects annual savings exceeding $900k after terminating SEC reporting and Nasdaq listing.","Stock purchase agreement with 3K/Kamin entities for up to $3.75M at $2.35/share to fund cash-out and working capital.","Transaction subject to stockholder approval at 2024 annual meeting expected in fall 2024; board may abandon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236013,"accession_number":"0001171843-24-003414","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Psychemedics dismisses BDO USA as auditor, engages Whitley Penn LLP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BDO USA as independent auditor on June 6, 2024; engaged Whitley Penn LLP on June 12, 2024.","No disagreements or reportable events with BDO in the two most recent fiscal years and interim period.","BDO's audit reports for fiscal years ended Dec 31, 2023 and 2022 were unqualified.","Company provided BDO with a copy of the statements and received BDO's letter to SEC agreeing with the statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236012,"accession_number":"0001171843-24-003243","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Psychemedics terminates Culver City lease; expects $250K net savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination effective June 30, 2024 for 5750 Hannum Ave, Culver City, CA.","Consideration payable to landlord is approximately $110,000.","Company expects $250,000 net cost savings over remaining lease term.","Original lease dated July 29, 2019 with Culver City/Hannum, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236011,"accession_number":"0001171843-24-002873","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics reports Q1 2024 revenue down 9% to $5.4M; net loss widens to $0.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.4M vs $5.9M in Q1 2023, a 9% decline.","Net loss $0.7M ($0.12 per share) vs loss of $0.4M ($0.07) in prior year.","CEO cites revenue decrease but remains optimistic; focusing on client acquisition and new market applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5357000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253758,"accession_number":"0001171843-24-001669","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics reports 2023 revenue down 12% to $22.1M, net loss widens to $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.1M in 2023, down 12% from $25.2M in 2022.","Net loss widened to $4.2M ($0.72 per share) from $1.1M loss ($0.19) in 2022.","Cash & equivalents fell to $2.0M from $4.8M at end of 2022.","Operating expenses increased to $11.3M from $10.4M, with G&A rising to $7.2M.","CEO cites ongoing labor shortage; plans cost reductions and pursuit of new markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253757,"accession_number":"0001171843-24-000431","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics sets 2024 CEO cash bonus target at $190,000; other execs at 25-40% of salary","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Brian Hullinger's 2024 bonus target is $190,000 with a maximum of $285,000 tied to financial and individual goals.","Other executive officers can earn cash bonuses of 25% to 40% of base salary under the 2024 plan.","Actual payouts are subject to Compensation Committee discretion after fiscal year-end performance review.","No changes to base salary or equity compensation were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271197,"accession_number":"0001171843-23-007278","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Psychemedics appoints Daniella Mehalik as VP-Finance and Treasurer, principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniella Mehalik, age 33, appointed VP-Finance and Treasurer, effective November 27, 2023.","She will serve as principal financial and accounting officer, reporting to CEO Brian Hullinger.","Compensation includes a base salary of $205,000; annual bonus target of 25% of base; 2024 bonus guaranteed at 10%.","Signing bonus of $10,000 subject to conditions; employment is at-will.","Ms. Mehalik previously served as Controller at NeuBase Therapeutics (NBSE) from 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271196,"accession_number":"0001171843-23-006962","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q3 revenue $5.7M (-12% YoY); net loss widens to $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.7M vs $6.5M YoY; net loss $(2.1M) or $(0.36)/diluted share vs $(0.02) loss.","Gross margin improved to 37% from 36%, cost programs partly offset revenue decline.","Operating expenses up 18% due to legal/settlement fees, CEO transition, and consulting.","Non-cash tax charge of $0.7M on deferred tax assets deemed unrealizable.","Restructuring initiated to align costs; new CRO Shannon Shoemaker leading go-to-market changes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":17100000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271195,"accession_number":"0001171843-23-006872","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics VP of Lab Ops Michael Schaffer departs effective Nov 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Schaffer ceased as VP of Laboratory Operations and employment on Nov 3, 2023.","No successor or reason for departure was disclosed in the filing.","The company thanked Dr. Schaffer for his years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288068,"accession_number":"0001171843-23-005839","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychomedics Assistant Controller Michael Weisenhoff resigns effective Sept 29, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Weisenhoff, Assistant Controller, resigned on Sept 20, 2023, effective Sept 29, 2023.","Resignation is to take a position with another company.","Company states the departure will not have a material impact on operations.","No successor named; transition expected to be handled internally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288067,"accession_number":"0001171843-23-005514","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics EVP Charles Doucot to depart Sept 15, 2023; severance per 2019 agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Executive Vice President Charles Doucot leaving effective September 15, 2023.","Severance benefits follow terms of February 26, 2019 severance agreement.","No replacement or further executive changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288066,"accession_number":"0001171843-23-005387","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Psychemedics grants 300,000 inducement options to new CEO; Nevin elected Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Inducement options to purchase 300,000 shares granted to CEO Brian Hullinger at $4.65/share exercise price.","Options vest in three tranches: 100,000 time-based over 2 years; 200,000 performance-based on stock price targets.","Darius G. Nevin elected Chairman of the Board, succeeding Raymond C. Kubacki who retired on August 17, 2023.","Annual meeting results: All six director nominees elected; advisory vote on exec compensation approved; BDO USA ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288065,"accession_number":"0001171843-23-005273","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q2 revenue down 15% to $5.5M, net loss widens; CEO transition, dividend eliminated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.5M vs $6.5M (-15%); net loss $(726,000) vs $(338,000); EPS $(0.13) vs $(0.06).","Gross margin improved to 37% from 35% on cost reductions; labor shortage hurt client testing volumes.","CEO Ray Kubacki retiring Aug 17; Brian Hullinger named President and CEO, pending board appointment.","Board eliminated dividend to maximize capital for growth initiatives.","Lawsuit settlement with consultant resulted in non-recurring expense; sum payable over 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":11396000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288064,"accession_number":"0001171843-23-004597","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Psychemedics settles contract dispute for $500K; records Q2 charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settled lawsuit with Transportation Insight LLC for $500,000 paid in three installments (first $166,667 in 30 days, then by Dec 2023 and Dec 2024).","Recorded a $500,000 settlement reserve in Q2 2023; company continues to deny liability and wrongdoing.","Settlement avoids potentially significant legal fees and management distraction from protracted litigation.","Agreement provides for dismissal of Georgia lawsuit (Case No. 2022CV369227) after payments; consent judgment secures obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288063,"accession_number":"0001171843-23-004498","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Psychemedics CEO Raymond Kubacki to retire; Brian Hullinger named successor as President/CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond Kubacki and director Fred Weinert retire effective Aug 17, 2023; controller William Norris resigns effective July 21.","Brian Hullinger appointed President/CEO effective Aug 17; base salary $375,000, target bonus $190,000 (2023 guaranteed).","Hullinger receives inducement option for 300,000 shares in three tranches: time-based and VWAP-linked targets.","Michael Weisenhoff appointed principal financial/accounting manager (salary $135,000) effective July 20.","Kubacki enters retirement agreement with consulting at $5,000/week; his 44,000 stock units fully vest on consulting end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308476,"accession_number":"0001171843-23-003111","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q1 revenue down 10% to $5.9M, net loss of $384K; declares $0.07 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $384K ($0.07 diluted loss) vs net income of $39K ($0.01 diluted) in Q1 2022.","Revenue fell 10% to $5.9M from $6.5M, driven by labor shortage and inflationary pressures.","Gross margin held flat at 38% due to cost reductions implemented in Q4 2022.","Cash balance $4.4M, equipment financing $0.5M; dividend of $0.07/share payable June 8 to record May 25.","Oil & Gas, Railroad, School segments performed solidly; fentanyl and benzodiazepine add-on test sales grew."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":5859000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327288,"accession_number":"0001171843-23-001806","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics reports flat FY2022 revenue; net loss widens to $0.19/sh; declares $0.07 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $25.2M (+1% YoY); net loss $1.1M or ($0.19) diluted EPS vs loss $0.7M ($0.12) prior year.","Q4 2022 revenue $5.7M (-11% YoY); net loss $0.7M or ($0.12) diluted EPS vs loss $1.6M ($0.29).","Board declared $0.07 quarterly cash dividend, payable April 10, 2023 to holders of record March 31, 2023.","Cash $4.8M, working capital $4.3M at year-end; equipment financing reduced to $0.6M.","Management cites labor shortage and inflation challenges; domestic revenue up 4% in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327287,"accession_number":"0001171843-23-001033","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics approves 2023 cash bonus plans for executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Compensation committee approved 2023 cash bonus arrangements for CEO, EVP, VP Lab Ops, and Controller.","Participants (excluding EVP) can earn up to 25% of base salary based on revenue, earnings, and individual goals.","EVP target is 20% base salary on revenue goal and 5% on earnings goal.","Committee retains right to withdraw, amend, or terminate bonus arrangements at any time.","Post-year-end CEO review will assess individual goal achievement for other participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345007,"accession_number":"0001171843-22-008275","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics appoints William Norris as Controller and principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Norris, 34, appointed Controller effective Jan 1, 2023, as principal financial and accounting officer.","Previously served as Assistant Controller since Aug 2022 and Accounting Manager from Apr 2021.","Salary $135,000 per year, at-will, eligible for cash performance bonus starting 2023.","Reports directly to CEO; CPA with MBA from Boston University and over 10 years of experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345006,"accession_number":"0001171843-22-007301","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q3 revenue down 3% to $6.5M, net loss of $0.1M; declares $0.07 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M vs $6.7M YoY (-3%); net loss $0.1M ($0.02/sh) vs net income $0.7M ($0.13/sh).","Nine-month revenue $19.5M (+5% YoY); net loss $0.4M ($0.07/sh) vs net income $1.0M ($0.17/sh).","Quarterly cash dividend of $0.07/sh declared, payable Dec 16, 2022 to holders of record Dec 2, 2022.","Prior-year quarter included $1.0M Employee Retention Credit; excluding ERC, gross margins were flat.","Cash $3.5M at Sep 30, 2022, up from $2.0M at Dec 31, 2021; equipment financing reduced to $0.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":19537000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361489,"accession_number":"0001171843-22-005702","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Psychemedics 2022 annual meeting: all directors elected, compensation approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected: Davis (3,299,451 for), Kamin (3,314,652), Kubacki (2,974,378), Nevin (3,333,632), Reynolds (3,179,137), Weinert (2,889,911).","Non-binding say-on-pay approved: 3,014,088 for, 294,829 against, 48,504 abstain.","Ratification of BDO USA, LLP as auditor for FY2022: 4,461,257 for, 36,257 against, 38,904 abstain.","Broker non-votes: 1,178,997 on director and compensation proposals; zero on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361488,"accession_number":"0001171843-22-005542","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q2 2022 revenue up 7% to $6.5M; net loss $0.3M vs net income $0.1M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M for Q2 2022, up 7% from $6.1M in Q2 2021; domestic revenue up 13% but Brazil down 65%.","Net loss of $0.3M ($0.06 diluted EPS) vs net income of $0.1M ($0.02 EPS) YoY; prior-year quarter had $0.8M ERC benefit.","Declared quarterly dividend of $0.07/share, payable Sept 9, 2022 to holders of record Aug 24, 2022.","Cash $1.8M and working capital $5.6M as of June 30, 2022; equipment financing down to $0.9M from $12.2M borrowed.","Continuing review of strategic alternatives; no assurance of any transaction or outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":13021000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361487,"accession_number":"0001171843-22-004980","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Controller Andrew Limbek resigns, will consult through his new firm","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Limbek resigned as VP-Controller, effective Aug 12, 2022, to join an international accounting firm.","He will assist the Corporation in an interim consulting role through his new firm, working with the finance team.","Mr. Limbek's resignation is not the result of any disagreement with the Corporation's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380817,"accession_number":"0001171843-22-004265","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Psychemedics adds two directors, Kamin and Nevin, expands board to six at Aug. 12 annual meeting; Tomenson retires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increases from 5 to 6 directors; Peter H. Kamin and Darius G. Nevin nominated for election at Aug. 12, 2022 annual meeting.","Walter S. Tomenson, Jr. will retire as director at the 2022 annual meeting after more than 20 years of service.","Cooperation Agreement with Kamin entities (beneficial owners of ~11.1% of PMD common stock) includes standstill until ~20 business days before 2023 annual meeting deadline.","Kamin and Nevin will serve on committees: Kamin on Compensation, Nominating, Strategic Alternatives; Nevin on Compensation, Audit, Strategic Alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380816,"accession_number":"0001171843-22-003516","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q1 revenue up 14% to $6.5M; declares increased dividend of $0.07/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M vs $5.7M (+14% YoY); domestic revenue up 17%, international down 42%.","Net income $39k ($0.01 diluted EPS) vs $83k; prior year included $800k ERC benefit.","Declares cash dividend of $0.07/share, payable June 24, 2022, to holders of record May 27, 2022.","Cash $2.1M, working capital $5.2M; equipment financing $1.1M, repaid $11.1M since May 2014.","Strategic alternatives review ongoing; CEO cites momentum in oil/gas, transport, and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":6508000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398879,"accession_number":"0001171843-22-002162","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics FY2021 revenue up 17% to $24.9M; net loss narrows to $0.7M from $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $24.9M (+17% YoY); net loss $0.7M ($0.12/diluted) vs $3.9M ($0.70) loss in 2020.","Q4 revenue $6.4M (+21% YoY) but Q4 net loss widened to $1.6M ($0.29/diluted) from $0.5M ($0.10).","PPP loan of $2.2M forgiven; $2.6M employee retention credits recognized; $3.3M in legal settlement charges.","Resumed quarterly dividend in Q4 2021 after pandemic suspension; board to evaluate future dividends.","Exploring strategic alternatives; year-end cash $2.0M, working capital $4.5M, equipment debt $1.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398878,"accession_number":"0001171843-22-002027","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Psychemedics appoints Andrew Reynolds to Board; Harry Connick retires effective Apr 4, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Reynolds elected to Board as independent director, effective April 4, 2022, filling vacancy from Harry Connick's retirement.","Reynolds brings over 25 years experience in strategy, corporate development, and trucking market, a key vertical for Psychemedics.","Reynolds will serve on Audit, Compensation, and Nominating & Governance Committees; granted 2,000 stock units upon appointment.","Harry Connick retires after 18 years on the Board, having chaired committees and served as former Orleans Parish District Attorney."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398877,"accession_number":"0001171843-22-001765","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Psychemedics furnishes investor presentation; content not available in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation materials intended for meetings with investors and other parties.","No specific financial or operational data from the presentation is provided in the query.","Filing is a routine Regulation FD disclosure without substantive new details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398876,"accession_number":"0001171843-22-000764","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Psychemedics approves 2022 cash bonus plan for execs; up to 25% of base salary","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bonus up to 25% of base salary based on domestic sales plan (7.5%), EPS target (7.5%), and individual goals (10%).","Participants include CEO, Executive VP, VP Lab Ops, and VP Controller.","CEO will assess other execs' individual goals; Compensation Committee determines final payouts.","Committee reserves right to amend or terminate bonus arrangements at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417849,"accession_number":"0001171843-21-008461","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Psychemedics settles California wage lawsuit for $1.15M, resumes dividend of $0.05/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding MOU to settle class action over CA wage/hour laws for ~$1.15M; company denies liability.","One-time non-cash charge of $1.15M expected in Q4 2021; cash payment anticipated in H2 2022.","Declares cash dividend of $0.05 per share, payable Dec 30, 2021 to holders of record Dec 20, 2021.","Continues strategic alternatives review; retained JMP Securities, Mintz Levin, and MTS Health Partners.","No timetable set for strategic review; no assurance of transaction or outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417848,"accession_number":"0001171843-21-007882","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q3 revenue up 29% to $6.7M; net income $0.13 EPS vs loss of $0.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.7M vs $5.2M YoY (+29%); domestic revenue up 27% YoY.","Net income of $0.7M ($0.13 diluted EPS) vs net loss of $1.1M (-$0.20).","Employee Retention Credit of $0.8M reduced costs; dividend remains suspended.","Exploration of strategic alternatives continues with JMP Securities; no timetable.","PPP loan of $2.2M fully forgiven by SBA in July 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":18473000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435423,"accession_number":"0001171843-21-006629","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Psychemedics settles contractual dispute for $1.925M, continues strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to pay customer $1.925M plus $150k from insurers to settle contractual dispute; payment due by Nov 30, 2021.","Dispute stemmed from customer's employee terminations over 15 years ago; no admission of liability by either party.","Board continues exploring strategic alternatives including sale or merger; JMP Securities and Mintz Levin retained as advisors.","Company expects to fund settlement from existing cash on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435422,"accession_number":"0001171843-21-005791","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Psychemedics Q2 2021 revenue up 85% to $6.1M, swings to net income of $0.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.1M vs $3.3M in Q2 2020 (+85%); net income $0.1M ($0.02 EPS) vs net loss $2.1M (-$0.37).","Domestic revenue up ~80%, driven by Oil & Gas, Manufacturing, Transportation segments; international revenue up 153% on small base.","Recorded $0.8M employee retention tax credit (ERC) under CAA; expects eligibility for Q3 and Q4 2021.","PPP loan of $2.2M fully forgiven by SBA in July 2021; cash $2.7M, working capital $7.1M as of June 30.","Dividend remained suspended since Q1 2020; board continues to evaluate quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":11800000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435421,"accession_number":"0001171843-21-004973","cik":806517,"company_name":"PSYCHEMEDICS CORP","ticker":"PMDI","form_type":"8-K","filed_at":"2021-07-20T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Psychemedics receives full forgiveness of $2.18M PPP loan from SBA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PPP loan principal of $2,181,157 plus accrued interest fully forgiven; forgiveness payment date July 1, 2021.","Loan originated May 1, 2020 from Bank of America at 1% interest, originally maturing May 4, 2022.","Forgiveness application submitted November 6, 2020; recognized in fiscal Q3 ending September 30, 2021.","Eliminates $2.18M liability and related interest obligation from the balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14686752.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}